E&G Advisors, LP Gilead Sciences, Inc. Transaction History

E&G Advisors, LP

$415 Million
Q3 2025

A detailed history of E&G Advisors, LP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, E&G Advisors, LP holds 16,589 shares of GILD stock, worth $1.99 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares

16,589

Previous 16,582 0.04%

Holding current value

$1.99 Million

Previous $1.84 Million 0.16%

% of portfolio

0.44%

Previous 0.49%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 20, 2025	BUY	$108.22 - $120.47 $757 - $843	7 Added 0.04%	16,589 $1.84 Million
Q2 2025 Jul 14, 2025	SELL	$96.91 - $113.0 $79,563 - $92,773	-821 Reduced 4.72%	16,582 $1.84 Million
Q1 2025 Apr 23, 2025	SELL	$89.14 - $117.41 $2,317 - $3,052	-26 Reduced 0.15%	17,403 $1.95 Million
Q4 2024 Jan 24, 2025	SELL	$83.95 - $97.9 $33,580 - $39,160	-400 Reduced 2.24%	17,429 $1.61 Million
Q4 2023 Jan 25, 2024	SELL	$73.27 - $83.09 $65,943 - $74,781	-900 Reduced 4.81%	17,829 $1.44 Million
Q3 2023 Oct 25, 2023	SELL	$73.94 - $80.67 $26,618 - $29,041	-360 Reduced 1.89%	18,729 $1.4 Million
Q1 2023 Jul 20, 2023	SELL	$77.31 - $88.08 $7,731 - $8,808	-100 Reduced 0.52%	19,089 $1.58 Million
Q1 2023 Apr 17, 2023	SELL	$77.31 - $88.08 $24,739 - $28,185	-320 Reduced 1.64%	19,189 $1.59 Million
Q4 2022 Jan 13, 2023	SELL	$62.32 - $89.47 $99,712 - $143,152	-1,600 Reduced 7.58%	19,509 $0
Q3 2022 Oct 11, 2022	SELL	$59.54 - $68.01 $35,724 - $40,806	-600 Reduced 2.76%	21,109 $1.3 Million
Q1 2022 Apr 12, 2022	BUY	$57.92 - $72.58 $17,376 - $21,774	300 Added 1.4%	21,709 $1.29 Million
Q3 2021 Oct 20, 2021	BUY	$67.69 - $73.03 $1.45 Million - $1.56 Million	21,409 New	21,409 $1.5 Million
Q2 2021 Jul 12, 2021	SELL	$63.47 - $69.35 $1.35 Million - $1.48 Million	-21,309 Closed	0 $1.48 Million
Q1 2021 Apr 12, 2021	SELL	$60.0 - $68.46 $22,440 - $25,604	-374 Reduced 1.72%	21,309 $1.38 Million
Q4 2020 Jan 26, 2021	BUY	$56.65 - $64.55 $16,995 - $19,365	300 Added 1.4%	21,683 $1.26 Million
Q3 2020 Oct 13, 2020	SELL	$62.1 - $78.08 $115,009 - $144,604	-1,852 Reduced 7.97%	21,383 $1.35 Million
Q1 2020 Apr 08, 2020	SELL	$62.63 - $80.22 $100,208 - $128,352	-1,600 Reduced 6.44%	23,235 $1.74 Million
Q3 2019 Oct 10, 2019	SELL	$62.51 - $69.0 $37,318 - $41,193	-597 Reduced 2.35%	24,835 $1.57 Million
Q2 2019 Jul 12, 2019	SELL	$61.87 - $69.38 $61,684 - $69,171	-997 Reduced 3.77%	25,432 $1.72 Million
Q1 2019 Apr 18, 2019	SELL	$62.53 - $70.05 $162,390 - $181,919	-2,597 Reduced 8.95%	26,429 $1.72 Million
Q4 2018 Jan 17, 2019	BUY	$60.54 - $79.0 $36,505 - $47,637	603 Added 2.12%	29,026 $1.82 Million
Q3 2018 Oct 10, 2018	BUY	$71.28 - $78.92 $87,032 - $96,361	1,221 Added 4.49%	28,423 $2.2 Million
Q2 2018 Jul 30, 2018	SELL	$64.88 - $75.68 $3,892 - $4,540	-60 Reduced 0.22%	27,202 $1.93 Million
Q1 2018 Apr 18, 2018	BUY	$72.84 - $88.8 $84,858 - $103,452	1,165 Added 4.46%	27,262 $2.06 Million
Q4 2017 Jan 16, 2018	SELL	$71.15 - $83.52 $92,352 - $108,408	-1,298 Reduced 4.74%	26,097 $1.87 Million
Q3 2017 Oct 20, 2017	BUY	$72.11 - $85.47 $1.98 Million - $2.34 Million	27,395	27,395 $2.22 Million

Others Institutions Holding GILD

# of Institutions

2,347

Shares Held

1.03B

Call Options Held

12.1M

Put Options Held

9.13M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $150B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E&G Advisors, LP, based on Form 13F filings with the SEC.

News

Stay updated on E&G Advisors, LP with notifications on news.

Account